PLCH1

Across TCGA pan-cancer cohorts, PLCH1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLCH1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLCH1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLCH1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where PLCH1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.754	0.977	.003	24	view →
LUAD	OS	Median	II,III,IV	0.911	0.434	.010	8	view →
PDAC	OS	Median	II,III,IV	0.514	0.257	.010	7	view →
LSCC	OS	Quartile	All	0.923	0.691	.014	3	view →
HNSC	OS	Quartile	All	0.650	0.913	.023	3	view →
GBM	DFS	Median	All	0.410	0.213	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLCH1–CCRCC (OS)

Open the CCRCC breakdown →